köp oxycontin i sverige No Further a Mystery
These actions involve class-huge basic safety labeling adjustments and new post-marketing and advertising specifications for all ER/LA opioid analgesics. FDA also responded to two citizen petitions regarding labeling of opioids. March: FDA achieved with companies of ER/LA opioid agony prescription drugs to discuss the requirement for a category-